Find clinical trials for Leukemia in Dallas, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia

B-Cell Chronic Lymphocytic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Myelodysplastic Syndromes

Myeloid Leukemia

Recurrence

Lymphoma

Leukemia trials near Dallas, TX, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...

Active, not recruiting

Acute Leukemia of Ambiguous Lineage

Mixed Phenotype Acute Leukemia

Drug: Ziftomenib

Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Dallas, Texas, United States and 43 other locations

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...

Active, not recruiting

Refractory Acute Leukemia of Ambiguous Lineage

Acute Myeloid Leukemia, in Relapse

Drug: Methotrexate

Drug: Venetoclax

Phase 1

St. Jude Children's Research Hospital

Dallas, Texas, United States and 7 other locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...

Active, not recruiting

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Lymphoma

Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn

Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital

Fort Worth, Texas, United States and 7 other locations

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...

Active, not recruiting

Acute Myelogenous Leukemia

Leukemia, Acute Myeloid

Drug: Iomab-B

Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals

Dallas, Texas, United States and 23 other locations

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting

Chronic Lymphocytic Leukemia

Prolymphocytic Leukemia

Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma

Fort Worth, Texas, United States and 11 other locations

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't r...

Enrolling

Acute Myeloid Leukemia

Drug: Pivekimab Sunirine

Phase 1

AbbVie

Dallas, Texas, United States and 10 other locations

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Active, not recruiting

Acute Myeloid Leukemia

Drug: BMF-500

Phase 1

Biomea Fusion

Dallas, Texas, United States and 13 other locations

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in...

Enrolling

Chronic Lymphocytic Leukemia

B-cell Malignancies

Drug: Emavusertib

Drug: Zanubrutinib

Phase 2

Curis

Dallas, Texas, United States and 10 other locations

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. (ALT-101)

4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.4A10 is a targeted therapy desi...

Enrolling

Acute Lymphoblastic Leukemia ALL

Lymphoblastic Lymphoma

Drug: 4A10

Phase 1

Allterum Therapeutics, Inc

Fort Worth, Texas, United States and 4 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting

Leukemia, Myeloid, Acute

Drug: Azacitidine

Drug: AG-120

Phase 1, Phase 2

Celgene

Dallas, Texas, United States and 48 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Leukemia in .css-epvm6{white-space:nowrap;}Dallas, TX

Related conditions:

Leukemia trials near Dallas, TX, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. (ALT-101)

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Find clinical trials for Leukemia in Dallas, TX